Achillion to Present at the Two Upcoming Healthcare Conferences

Fri Sep 6, 2013 4:05pm EDT

* Reuters is not responsible for the content in this press release.

NEW HAVEN, Conn., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:

  • Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013 at 3:50 p.m. ET at Grand Hyatt New York, in New York, NY; and
     
  • Baird's 2013 Health Care Conference on Tuesday, September 10, 2013 at 1:45 p.m. ET at The New York Palace Hotel in New York, NY.

The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's discovery, clinical development, and commercial teams have advanced multiple novel product candidates with proven mechanisms of action into studies and toward the market. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.

CONTACT: Company Contact:
         Glenn Schulman
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 752-5510
         gschulman@achillion.com
         
         Investors:
         Mary Kay Fenton
         Achillion Pharmaceuticals, Inc.
         Tel. (203) 624-7000
         mfenton@achillion.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.